Bessemer Group Inc. Has $694,000 Stock Holdings in Charles River Laboratories International, Inc. $CRL

Bessemer Group Inc. decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 34.0% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,578 shares of the medical research company’s stock after selling 2,357 shares during the quarter. Bessemer Group Inc.’s holdings in Charles River Laboratories International were worth $694,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in CRL. Brooklyn Investment Group grew its holdings in shares of Charles River Laboratories International by 93.5% in the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after purchasing an additional 86 shares during the last quarter. Cromwell Holdings LLC grew its holdings in shares of Charles River Laboratories International by 542.9% in the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock worth $27,000 after purchasing an additional 152 shares during the last quarter. HM Payson & Co. bought a new stake in shares of Charles River Laboratories International in the 1st quarter worth about $31,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Charles River Laboratories International in the 2nd quarter worth about $56,000. Finally, Bayforest Capital Ltd bought a new stake in shares of Charles River Laboratories International in the 2nd quarter worth about $63,000. Institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on CRL. Jefferies Financial Group raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and upped their target price for the stock from $142.00 to $195.00 in a report on Tuesday, September 9th. Mizuho increased their price objective on shares of Charles River Laboratories International from $155.00 to $174.00 and gave the stock a “neutral” rating in a report on Friday, October 17th. Weiss Ratings reissued a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, October 8th. Wall Street Zen lowered shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 23rd. Finally, Evercore ISI increased their price objective on shares of Charles River Laboratories International from $190.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, October 3rd. Eight research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $181.29.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $180.17 on Friday. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $230.02. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. The business’s 50-day moving average price is $167.05 and its two-hundred day moving average price is $152.98. The stock has a market cap of $8.87 billion, a PE ratio of -135.46, a P/E/G ratio of 4.83 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.62. The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The business’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.80 earnings per share. As a group, analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of the business’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the sale, the executive vice president directly owned 24,116 shares in the company, valued at approximately $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).